Because they cause C-cell hyperplasia in rodent models, GLP-1 based drugs are contraindicated in patients with personal or family histories of medullary thyroid cancer or multiple endocrine neoplasia type 2. The gene discussed is GCG; the disease is multiple endocrine neoplasia type 2.